Kos Will Re-Launch Teveten And Cardizem LA In June Following Biovail Deal
Executive Summary
Kos will re-launch Biovail's three cardiovascular products in June following the addition of 150 Biovail reps to its sales team
You may also be interested in...
Biovail Focus Is Product Development After Divesting Primary Care Sales Reps
Biovail will focus on "recharging its drug development portfolio" as the company moves forward after divesting its primary care sales force, Senior VP-R&D Gregory Szpunar said May 5
Biovail Focus Is Product Development After Divesting Primary Care Sales Reps
Biovail will focus on "recharging its drug development portfolio" as the company moves forward after divesting its primary care sales force, Senior VP-R&D Gregory Szpunar said May 5
Zyprexa Patent Valid: Lilly’s Phase I Olanzapine Trials Were Not “Public Use”
Lilly's conduct of Phase I clinical trials for Zyprexa prior to applying for a composition/use patent did not constitute a prior "public use" that would render the patent invalid, an Indianapolis federal judge ruled April 14